{
    "root": "2f1fa6e7-20a7-47c5-a8fe-6ade26ea89c8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin",
    "value": "20250203",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q"
        }
    ],
    "indications": "Rosuvastatin tablets are indicated: \n    • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.  \n    • As an adjunct to diet to: \n          o Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. \n          o Reduce LDL-C and slow the progression of atherosclerosis in adults. \n          o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). \n    • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). \n    • As an adjunct to diet for the treatment of adults with: \n          o Primary dysbetalipoproteinemia. \n          o Hypertriglyceridemia.",
    "contraindications": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating  rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for rosuvastatin dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions": "Rosuvastatin Tablets USP are supplied as:\n                  20 mg: Light pink to pink, round, bevel edged biconvex film coated tablets, debossed with 'H' on one side and 'R5' on the other side.\n                  \n                     NDC 71335-9669-1: 30 Tablets in a BOTTLE\n                     NDC 71335-9669-2: 90 Tablets in a BOTTLE\n                     NDC 71335-9669-3: 28 Tablets in a BOTTLE\n                     NDC 71335-9669-4: 60 Tablets in a BOTTLE\n                     NDC 71335-9669-5: 180 Tablets in a BOTTLE\n                     NDC 71335-9669-6: 120 Tablets in a BOTTLE\n                  \n                  StorageStore at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Rosuvastatin is contraindicated in the following conditions: \n    • Acute liver failure or decompensated cirrhosis\n \n  [see \n  \n   Warnings and Precautions (5.3)].\n \n  \n                       • Hypersensitivity to rosuvastatin or any excipients in rosuvastatin. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin\n \n  [see\n  \n   Adverse Reactions (6.1)]."
}